Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Comerica Bank

Comerica Bank decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) by 9.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,453 shares of the specialty pharmaceutical company’s stock after selling 4,485 shares during the quarter. Comerica Bank’s holdings in Supernus Pharmaceuticals were worth $1,405,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Exchange Traded Concepts LLC boosted its position in shares of Supernus Pharmaceuticals by 2.3% during the 2nd quarter. Exchange Traded Concepts LLC now owns 19,472 shares of the specialty pharmaceutical company’s stock valued at $563,000 after acquiring an additional 444 shares during the last quarter. Meritage Portfolio Management boosted its position in shares of Supernus Pharmaceuticals by 4.5% during the 3rd quarter. Meritage Portfolio Management now owns 12,236 shares of the specialty pharmaceutical company’s stock valued at $414,000 after acquiring an additional 524 shares during the last quarter. Campbell Newman Asset Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 2.5% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 24,298 shares of the specialty pharmaceutical company’s stock valued at $822,000 after acquiring an additional 583 shares during the last quarter. First National Bank of Omaha boosted its position in shares of Supernus Pharmaceuticals by 4.0% during the 2nd quarter. First National Bank of Omaha now owns 17,033 shares of the specialty pharmaceutical company’s stock valued at $493,000 after acquiring an additional 662 shares during the last quarter. Finally, Ziegler Capital Management LLC raised its holdings in Supernus Pharmaceuticals by 2.8% in the 2nd quarter. Ziegler Capital Management LLC now owns 26,396 shares of the specialty pharmaceutical company’s stock valued at $763,000 after buying an additional 719 shares during the period. Institutional investors and hedge funds own 99.82% of the company’s stock.

Supernus Pharmaceuticals Trading Down 0.2 %

Shares of SUPN opened at $40.31 on Monday. The firm has a market cap of $2.18 billion, a P/E ratio of 62.98 and a beta of 0.94. Supernus Pharmaceuticals, Inc. has a 12-month low of $24.95 and a 12-month high of $41.19. The company’s 50-day moving average price is $36.76 and its 200 day moving average price is $34.33.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last issued its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.29). The business had revenue of $177.35 million for the quarter, compared to analysts’ expectations of $173.22 million. Supernus Pharmaceuticals had a return on equity of 4.51% and a net margin of 5.72%. Equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.63 earnings per share for the current year.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 1,115 shares of the business’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $35.00, for a total transaction of $39,025.00. Following the sale, the chief executive officer now directly owns 780,742 shares in the company, valued at $27,325,970. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 1,115 shares of the business’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $35.00, for a total transaction of $39,025.00. Following the sale, the chief executive officer now directly owns 780,742 shares in the company, valued at $27,325,970. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 4,826 shares of the business’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $39.92, for a total transaction of $192,653.92. Following the sale, the vice president now owns 1,644 shares in the company, valued at $65,628.48. The disclosure for this sale can be found here. Insiders have sold 69,340 shares of company stock worth $2,629,303 over the last three months. Company insiders own 7.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, January 13th. Piper Sandler reduced their price objective on shares of Supernus Pharmaceuticals from $38.00 to $36.00 in a report on Tuesday, October 11th.

Supernus Pharmaceuticals Company Profile

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Featured Articles

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.